R2 Technology Partners with Kaiser Permanente for CAD Technology Deployment

Strategic Insights -

R2 Technology Inc. has partnered with Kaiser Permanente to provide CAD systems to all Kaiser Permanente facilities. The agreement, which extends through December 31, 2005, will grant Kaiser Permanente access to R2 Technology's ImageChecker(R) CAD system with the OmniCAD(TM) platform for early breast cancer detection. This partnership aims to leverage the ImageChecker system's capabilities to enhance radiology services and improve patient outcomes.

Key Takeaways:

  • R2 Technology has signed a two-year agreement with Kaiser Permanente to provide CAD systems to all Kaiser Permanente facilities, extending through December 31, 2005.
  • The agreement grants Kaiser Permanente access to R2 Technology's ImageChecker(R) CAD system with the OmniCAD(TM) platform for early breast cancer detection.
  • Over 8 million women worldwide have had their mammograms interpreted with the aid of the ImageChecker CAD system, with over 1,200 systems shipped globally.
  • Kaiser Permanente's research partnership with R2 Technology has been invaluable in the development of the ImageChecker CAD system, with ongoing research collaborations at San Francisco and Redwood City facilities.
  • Studies have shown that CAD can improve breast cancer detection rates by 23.4 percent, surpassing double reading methods and meeting medical standards.
  • The American Cancer Society has recognized CAD as a new technology for breast cancer screening, with guidelines advocating its use for women of average risk.

Statistics:

  • Over 8 million women worldwide have had their mammograms interpreted with the aid of the ImageChecker CAD system.
  • More than 1,200 ImageChecker systems have been shipped globally.
  • Clinical trials have demonstrated that use of the ImageChecker CAD system can result in earlier detection of up to 23.4 percent of cancers currently detected with screening mammography.

Sources:

Source 1: R2 Technology Press Release, SUNNYVALE, Calif., Jan 23 /PRNewswire/

Source 2: Kaiser Permanente

Source 3: R2 Technology

Source 4: American Cancer Society